AAM Departures Lead To Change Of Chair For IGBA

Trio Of Executives Leave US Association, Including IGBA Chair For 2023

The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.

Revolving Doors Executives Blurred
Three executives have left the AAM, leading the IGBA to seek a new chair • Source: Shutterstock

Three senior executives at the Association for Accessible Medicines have seen their positions eliminated at the industry body as a result of the latest budgetary measures deployed by the US generics and biosimilars association.

The three affected roles are those of Allen Goldberg, the AAM’s senior vice-president for communications; Erik Komendant, the association’s senior vice-president of government affairs; and Jonathan Kimball, vice-president for trade,...

More from Agency Leadership

More from Pink Sheet

EMA Says Digital Transformation A ‘Fundamental Shift’ In Meeting Regulatory Challenges

 

Sponsors can expect faster evaluation processes for key medicines and greater support in mitigating medicines supply shortages this year as part of the European Medicines Agency’s digital transformation overhaul.

EU CHMP Opinions And MAA Updates

 

This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.

HHS Rescinds COVID-19 Vaccine Advice, Usurping US CDC Role

 
• By 

By stepping into the role of the Centers for Disease Control and Advisory Committee on Immunization Practices, HHS Secretary Robert F. Kennedy Jr. is causing further confusion and uncertainty about vaccine policy, experts say.